RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cellectar Biosciences - Stock

Cellectar Biosciences ROE 2024

Cellectar Biosciences ROE

28.01

Ticker

CLRB

ISIN

US15117F5008

WKN

A2NB71

In 2024, Cellectar Biosciences's return on equity (ROE) was 28.01, a -1,619.03% increase from the -1.84 ROE in the previous year.

Cellectar Biosciences Aktienanalyse

What does Cellectar Biosciences do?

Cellectar Biosciences is a biotechnology company specializing in the development of innovative cancer therapies. It was founded in 2003 and is headquartered in Madison, Wisconsin, USA. The company's mission is to revolutionize cancer treatment by developing therapies with high efficacy. Cellectar Biosciences focuses on research and development in the areas of preclinical development, clinical trials, and product registration. It has expanded its business to include radiation therapy and imaging diagnostics. The company is divided into different divisions for effective work and specialization. It has partnerships with leading players in the biotechnology industry. Overall, Cellectar Biosciences has built an impressive portfolio of products and services to meet the needs of patients and healthcare providers and will continue to play a significant role in the biotechnology industry in the future. Cellectar Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Cellectar Biosciences's Return on Equity (ROE)

Cellectar Biosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cellectar Biosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cellectar Biosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cellectar Biosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cellectar Biosciences Stock

What is the ROE (Return on Equity) of Cellectar Biosciences this year?

The ROE of Cellectar Biosciences this year is 28.01 undefined.

How has the Return on Equity (ROE) of Cellectar Biosciences developed compared to the previous year?

The ROE of Cellectar Biosciences has increased by -1,619.03% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Cellectar Biosciences?

A high ROE indicates that Cellectar Biosciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Cellectar Biosciences?

A low ROE can indicate that Cellectar Biosciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Cellectar Biosciences affect the company?

A change in ROE (Return on Equity) of Cellectar Biosciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Cellectar Biosciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Cellectar Biosciences?

Some factors that can influence Cellectar Biosciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Cellectar Biosciences pay?

Over the past 12 months, Cellectar Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectar Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Cellectar Biosciences?

The current dividend yield of Cellectar Biosciences is .

When does Cellectar Biosciences pay dividends?

Cellectar Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cellectar Biosciences?

Cellectar Biosciences paid dividends every year for the past 0 years.

What is the dividend of Cellectar Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cellectar Biosciences located?

Cellectar Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cellectar Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cellectar Biosciences from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Cellectar Biosciences pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Cellectar Biosciences in the year 2023?

In the year 2023, Cellectar Biosciences distributed 0 USD as dividends.

In which currency does Cellectar Biosciences pay out the dividend?

The dividends of Cellectar Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cellectar Biosciences

Our stock analysis for Cellectar Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectar Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.